Is the advance market commitment designed for multinational pharmaceutical firms, rather than the emerging suppliers?
The commitment is neutral about which type or types of suppliers would benefit. While multinational firms have a longer track record of innovation and ability to deliver new products, emerging suppliers are increasingly demonstrating capacity to undertake research (particularly at the clinical phases) and have a significant advantage in scale manufacturing for some types of products. It is likely that, as a market is defined through an advance market commitment, partnerships between innovators and manufacturers of all types will be created; some of these may favor emerging suppliers. Unlike funding for which sponsors pick the recipients from the beginning, an advance market commitment creates a level playing field on which suppliers of all types can compete.
